George Papatheodoridis
George Papatheodoridis is an expert in Hepatology at Laiko General Hospital of Athens (Greece). As of October 2026, ScienceLeadR ranks George Papatheodoridis in the top 1% of experts worldwide for Hepatitis. George Papatheodoridis has authored 717 publications, the most recent in 2026, and is an investigator in 19 clinical trials, 3 of them ongoing. SLR score: 2,813 (community average: 125). How the SLR is computed.
LeadR Profile
Hepatology
Subspecialties: Gastroenterology
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 2000 - 2026
Number : 717
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| High Prevalence of Pruritus, Fatigue, and Sleep Disorders in MASLD Negatively Affects Health-related Quality of Life and Work Productivity. PMID 42925568 — depression, quality of life, sleep, non-alcoholic fatty liver disease, signs and symptoms, pruritus, fatigue, work, prevalence, sleep initiation and maintenance disorders | J Clin Gastroenterol | 2026 | 0 |
| Efficacy and Safety of Ozanimod in Ulcerative Colitis: A Real-World Pan-Hellenic Study. PMID 42796318 — colitis, safety, treatment failure, inflammatory bowel diseases, therapeutics, colitis, ulcerative | Medicina (Kaunas) | 2026 | 0 |
| Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma: Summary of the First Annual Paris International Liver Meeting 2026. PMID 42613687 — liver diseases, hypertension, carcinoma, hepatocellular, cholangitis, fibrosis, non-alcoholic fatty liver disease, liver, hypertension, portal, therapeutics, hepatitis, peroxisome proliferator-activated receptors | Liver Int | 2026 | 0 |
| Postbleeding antithrombotic management in cardiovascular patients: insights from the Attica Bleeding Snapshot study. PMID 42598058 — mortality, hemorrhage, hospital mortality, atrial fibrillation, therapeutics, frailty | Res Pract Thromb Haemost | 2026 | 0 |
| Adiposity and Cumulative Cardiometabolic Risk Factors as Determinants of Hepatic Steatosis Severity in Postmenopausal Women. PMID 42590200 — liver diseases, body mass index, cardiometabolic risk factors, liver, adiposity, risk factors, menopause, waist circumference, sex hormone-binding globulin | J Clin Med | 2026 | 0 |
Clinical Studies 19
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A study to investigate the safety and efficacy of GSK4532990 compared with placebo in adult participants aged 18 to 70 years with alcohol related liver disease 2024-511596-15-00 — liver diseases, safety, liver, aged | Phase 2 | Recruiting | 2024 |
| HEllenic Multicenter ReAl life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D HERACLIS BLV NCT05928000 — tenofovir, hepatitis d, leukemia virus, bovine, hepatitis d, chronic, hepatitis, chronic, hepatitis a, therapeutics, hepatitis | N/A | Recruiting | 2023 |
| Research Study on Whether Semaglutide Works in People With Non alcoholic Steatohepatitis (NASH) NCT04822181 — liver diseases, skin, non-alcoholic fatty liver disease, liver, alcoholics, research, fatty liver, fatty liver, alcoholic, semaglutide | Phase 3 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map